IL116997A0 - Transdermal formulation - Google Patents

Transdermal formulation

Info

Publication number
IL116997A0
IL116997A0 IL11699796A IL11699796A IL116997A0 IL 116997 A0 IL116997 A0 IL 116997A0 IL 11699796 A IL11699796 A IL 11699796A IL 11699796 A IL11699796 A IL 11699796A IL 116997 A0 IL116997 A0 IL 116997A0
Authority
IL
Israel
Prior art keywords
transdermal formulation
transdermal
formulation
Prior art date
Application number
IL11699796A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL116997A0 publication Critical patent/IL116997A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11699796A 1995-02-17 1996-02-01 Transdermal formulation IL116997A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39044595A 1995-02-17 1995-02-17
US48101695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
IL116997A0 true IL116997A0 (en) 1996-06-18

Family

ID=27013141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11699796A IL116997A0 (en) 1995-02-17 1996-02-01 Transdermal formulation

Country Status (22)

Country Link
US (1) US5858393A (no)
EP (1) EP0727208B1 (no)
JP (1) JPH11505513A (no)
KR (1) KR19980702239A (no)
CN (1) CN1181007A (no)
AR (1) AR002027A1 (no)
AU (1) AU700023B2 (no)
BR (1) BR9607722A (no)
CA (1) CA2212874A1 (no)
CO (1) CO4700408A1 (no)
CZ (1) CZ255097A3 (no)
DE (1) DE69614419T2 (no)
ES (1) ES2159683T3 (no)
FI (1) FI973362A (no)
HU (1) HUP9802070A3 (no)
IL (1) IL116997A0 (no)
NO (1) NO973715L (no)
NZ (1) NZ302147A (no)
PE (1) PE17897A1 (no)
TR (1) TR199700799T1 (no)
WO (1) WO1996025154A1 (no)
YU (1) YU6196A (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2001030316A2 (en) * 1999-10-28 2001-05-03 3M Innovative Properties Company Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009143188A2 (en) * 2008-05-19 2009-11-26 Diperna Paul M Disposable pump reservoir and related methods
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
EP2363116A1 (en) 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) * 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
PT714394E (pt) * 1993-08-19 2001-12-28 Novo Nordisk As Metodo antipsicotico com derivados de tiadiazol e oxadiazol

Also Published As

Publication number Publication date
CZ255097A3 (en) 1997-12-17
HUP9802070A2 (hu) 1999-02-01
AR002027A1 (es) 1998-01-07
DE69614419D1 (de) 2001-09-20
PE17897A1 (es) 1997-06-12
ES2159683T3 (es) 2001-10-16
AU700023B2 (en) 1998-12-17
YU6196A (sh) 1998-09-18
CA2212874A1 (en) 1996-08-22
AU4774296A (en) 1996-09-04
WO1996025154A1 (en) 1996-08-22
CN1181007A (zh) 1998-05-06
EP0727208B1 (en) 2001-08-16
KR19980702239A (ko) 1998-07-15
CO4700408A1 (es) 1998-12-29
FI973362A0 (fi) 1997-08-15
TR199700799T1 (xx) 1998-02-21
US5858393A (en) 1999-01-12
HUP9802070A3 (en) 2000-09-28
JPH11505513A (ja) 1999-05-21
DE69614419T2 (de) 2002-05-23
MX9706143A (es) 1997-11-29
NZ302147A (en) 1998-10-28
NO973715D0 (no) 1997-08-12
BR9607722A (pt) 1998-07-14
NO973715L (no) 1997-08-12
FI973362A (fi) 1997-08-15
EP0727208A1 (en) 1996-08-21

Similar Documents

Publication Publication Date Title
GB9514842D0 (en) Novel formulation
EP0846088A4 (en) CEMENT FORMULATION
GB9519363D0 (en) Pharmaceutical formulation
GB9402029D0 (en) Novel formulation
EP0862431A4 (en) PHARMACEUTICAL PREPARATION
HUP9800832A3 (en) Transdermal formulation
IL116997A0 (en) Transdermal formulation
IL116999A0 (en) Transdermal formulation
GB9523566D0 (en) Pharmaceutical formulation
GB2307857B (en) An effervescent formulation
ZA976592B (en) Formulation
AU6708996A (en) Transdermal nitrate formulation
HU9602732D0 (en) Lanperisone formulation
ZA96797B (en) Transdermal formulation.
GB9404989D0 (en) Lipomimetric formulation
GB9508684D0 (en) Novel formulation
AUPN493095A0 (en) Transdermal composition
GB9412642D0 (en) Formulation
GB9423416D0 (en) Formulation
GB9412641D0 (en) Formulation
GB9416500D0 (en) Formulation
ZA952272B (en) Formulation
GB9502786D0 (en) Pharmaceutical formulation
GB9525386D0 (en) Pharmaceutical formulation
GB9509559D0 (en) Gel formulation